| Publikacja | Impact Factor |
|---|---|
| 2015 | |
| Truszkowska GT, Bilińska ZT, Kosińska J, Śleszycka J, Rydzanicz M, Sobieszczańska-Małek M, Franaszczyk M, Bilińska M, Stawiński P, Michalak E, Małek ŁA, Chmielewski P, Foss-Nieradko B, Machnicki MM, Stokłosa T, Ponińska J, Szumowski Ł, Grzybowski J, Piwoński J, Drygas W, Zieliński T, Płoski R. A study in Polish patients with cardiomyopathy emphasizes pathogenicity of phospholamban (PLN) mutations at amino acid position 9 and low penetrance of heterozygous null PLN mutation BMC Med Genet. 2015 Apr 3;16(1):21. | 2,5 |
| 2014 | |
| Glodkowska-Mrowka E, Mrowka P, Basak GW, Niesiobedzka-Krezel J, Seferynska I, Wlodarski PK, Jakobisiak M, Stoklosa T. Statins inhibit ABCB1 and ABCG2 drug transporters activity in chronic myeloid leukemia cells and potentiate antileukemic effects of imatinib. Exp Hematol. 2014 Jun;42(6):439-4. | 2,8 |
| Machnicki MM, Stoklosa T. BRAF – A new player in hematological neoplasms. Blood Cells Mol Dis. 2014 Feb 1. pii: S1079-9796(14)00002-3. | 2,3 |
| Glodkowska-Mrowka E, Solarska I, Mrowka P, Bajorek K, Niesiobedzka-Krezel J, Seferynska I, Borg K and Stoklosa T. Differential expression of BIRC family genes in chronic myeloid leukaemia – BIRC3 and BIRC8 as potential new candidates to identify disease progression. British Journal of Haematology 2014; 164(5):740-2. | 4,9 |
| 2013 | |
| Nieborowska-Skorska M, Hoser G, Hochhaus A, Stoklosa T, Skorski T. Anti-oxidant vitamin E prevents accumulation of imatinib-resistant BCR-ABL1 kinase mutations in CML-CP xenografts in NSG mice.Leukemia. 2013 Nov;27(11):2253-4. | 9,3 |
| Bolton-Gillespie E, Schemionek M, Klein HU, Flis S, Hoser G, Lange T, Nieborowska-Skorska M, Maier J, Kerstiens L, Koptyra M, Müller MC, Modi H, Stoklosa T, Seferynska I, Bhatia R, Holyoake TL, Koschmieder S, Skorski T. Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells.Blood. 2013 May 16;121(20):4175-83. | 9,7 |
| Machnicki MM, Glodkowska-Mrowka E, Lewandowski T, Ploski R, Wlodarski P, Stoklosa T. ARMS-PCR for detection of BRAF V600E hotspot mutation in comparison with Real-Time PCR-based techniques.Acta Biochim Pol. 2013;60(1):57-64. | 1,3 |
| Stoklosa T, Glodkowska-Mrowka E, Hoser G, Kielak M, Seferynska I, Wlodarski P. Diverse mechanisms of mTOR activation in chronic and blastic phase of chronic myelogenous leukemia.Exp Hematol. 2013 May;41(5):462-9. | 2,8 |
| Slupianek A, Falinski R, Znojek P, Stoklosa T, Flis S, Doneddu V, Pytel D, Synowiec E, Blasiak J, Bellacosa A, Skorski T. BCR-ABL1 kinase inhibits uracil DNA glycosylase UNG2 to enhance oxidative DNA damage and stimulate genomic instability.Leukemia. 2013 Mar;27(3):629-34. | 9,3 |
|
2012 |
|
| Kusio-Kobialka M, Podszywalow-Bartnicka P, Peidis P, Glodkowska-Mrowka E, Wolanin K, Leszak G, Seferynska I, Stoklosa T, Koromilas AE, Piwocka K. The PERK-eIF2α phosphorylation arm is a pro-survival pathway of BCR-ABL signaling and confers resistance to imatinib treatment in chronic myeloid leukemia cells. Cell Cycle. 2012 Nov 1;11(21):4069-78. | 5,2 |